Plasma atrial and brain natriuretic peptides in elderly patients with heart failure due to diastolic vs. systolic left ventricular dysfunction  by Marburger, C.T. et al.
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• Falling of I.eft Ventrlcular/3 Adrenerglc Affinity In 
a Canine Model  o f  Obesity.Hypertension 
P, Cabrol. M. Gallnler, J. Fourcade. P. L(~ger. J L Montaetruc. 
J,P, Bounhouro, J,M, Fauvel, J,M, S(~nard, University of Toulouse, France 
Background: Obesity consfltues a classic supplier of cardiovascular diseases, 
This work auese cardiac P adrenerglc phanotypo In obesity hypertension 
before heart failure appears1 
Method=: Six beagle dogs (aged 35 .~. 5 monlhs) receiving during 30 
weeks a high.fat dial worn compared to 6 normal beagle dogs, Cardle(~ 
p edrenarglo soapier density wore measured by a binding study with 
todeoyanoplndotoL/11 and p2 densities ware obtained by competition with 
CGP 2O?t 2A, Affinity state of p ¢ldrenergto scepter was Msassed by comps. 
tttlon with IJopmtamnoL Noredrenallna plasma Level was essayed by HPLC, 
Left ~ntfloular mass warn maesumd by eohocardlography. 
R~u~: Systello blood pressure was higher In obeses (245 ± 8 vs 19"/~t 
10 mmHg In oontmls), Diastolic blood pressure didn't differed between both 
group (93 ± 3 va 84 ;L 3 mmHg in controls), NoredreneUna plasma levels 
were not dlffamnts between the both groups (276 ~ 30 vs 235 ± 50 pg/ml in 
eontretM, Ob~ses were characterized hy higher felt vontricular mass (80 t 
24 ~ S? ~ 1~ g in controls), p.AR right aurioulsr and lair ventric~uter density 
were not respectively dtffemnt in obeses (5? ~ 6 and O? ~- 4 temteM/mg 
pfotalnl ~ompared to oontrela (68 .t ? And 63 ~: 9 temtoM/mg pmteln), # f,AR 
proportion were the ~me between abases and (mntrels in right ~uneular (03 
.~; 4 w 04 ~ 3% in nontmts) and left vantnoular (59 t 3 vs 60 :is 4% in 
nontrels), Proportion el f¢,AR receptors in a high a~lntty state were the same 
in aurioular sample (69 ± 4 vs 87 ~ 3% in controls) but was different in left 
vontn~ular (~8 ± ~1 va 74 ± 0% in controls) 
Conctt~0n: Latt vantrlCular ,,l,edmnocaplor came under a specific de. 
aensibllisatlon in this obesity,hypertension model Independent of plasma 
noredrsnallno levels, Thts changes may account to the progressive systolic 
dysfunotlon, 
~ De©reseed Ex©mtlon of  Urodllatln In Urinary 
l~It lantt With Essential Hypertension 
Y,-S, Hwang, Y,-J. Lea, J,.D, Wen, S,-J, Shin, J,.H, "Pant, Kaohsiung Medic.It 
Ba!ckgtound: Urodilettn is n renal syntheai~d peptide with potent natriurotlc 
activity and Is thought to play ¢1 rote in the renal handling of sodium home- 
coral=is, This study Is destgned to Investigate the possible role of urodilatin in 
the pathoponesla of essential hypertension (EH), 
Meltlod~: Urinary atrial netriuretic pepltde,llke immunoraactWtty (ANP-I.I) 
excretion was measured by radlolmmunoassay (RIA) after extraction in 
twenty.three EH patients without any detectable target organ damage end 
eleven normotenstve control subie¢ts, High performance liquid chromatogra- 
phy (HPLC) coupled with RIA was used to characterize the molecular natures 
of ANP-LI In the urine Urinary concentrations of uroditetin were measured 
by a competitive ELISA with urodilatin specific antibody, 
Results," Udnary excretion of ANP-LI in patients with EH (13,7 • 1,8 
ng/d~.y) was not significantly different from that of control subjects 04,4 ± 
2,4 ng/dey), The HPLC couples with RIA revealed that the major components 
of ANP,LI In the urine are ,~.hANP and urodtlatln. The molar ratio of =~-hANP: 
umdllattn in the urine was 40.9:59,1 in normal subjects, while the urodilatLn 
molar ratio is slgn(ficantty decreased in patients with EH (71,3: 28.7), 
Conclusion" The decreased urodilatln excretion in patients with EH may 
suggesl that urodilattn is involved in the pathogenesis of EH, 
~ Transforming Growth Factor/32 Levels In Patients 
With Essential  Hypertension - The Effect o f  
Ant lhypertenslve Treatment With Ramlprll 
Th,K, Makes. P.~. Krospi, A,N, Hatzizachartas. V,E, Voftoas, 
E.B. Chronakis. C.G. Tsoukala, N,G, Stratigts, M,K, Kyriakidis, Cardiology 
Dept. 2rid Rag, BTC.Hsemoof, Lat~, Laikon Gee, Heap,. Athens. Greece 
Background: Transforming Growth Factor {TGF) acts either as an inhibitor or 
as stimulant of proliferation and differentiation or by modulating cell functions. 
It has been also implicated with a variety of other locally synthesized factor~ 
in dramatic structural disorders in pathologies uch as atherosclerosis and 
hypertension. The aim of our study was: a) to determine TGF~ levels in 
hypertensive patients (pts) and b) to examine the effect of antihypertensive 
treatment (i,e, ramipril) on the TGF~ levels in the same population. 
Methods: 43 hypertensives (20 M, 23 F) mean age 52,2 ± 10.6 yrs with 
mild to moderate arterial hypertension (DBP 100 "± 9 mmHg. Group H) an ~1 
40 healthy volunteers (19 M, 21 F) mean age 48,7 ± 10.3 yrs (Group N) 
were studied. Blood sampling was performed at 8-9 am after 12 hours of 
fasting. TGF~ levels were assayed by ELISA. In the hypertensive group 
measurements were made before (baseline) and six months after therapy 
with ramipril. 
Results: The TGF~= plasma levels were significantly higher In the hyper- 
tensive group (38.9 ± 5,3 pg/ml) than in healthy volunteers (36,25 ± 3,99 
pg/mt) p < 0.05, Antlhypertenslva therapy with ramlpril had a favorable effect, 
i.e. significant decrease of the TGF~ levels In the hypertensive group (35.72 
,~ 4,6S vs 38.9 ± 5,3 pg/ml, p -~ 0.0f). 
Conclusion: Our findings suggest that TGF~ levels are significantly in- 
creased In hypertensives compared to healthy volunteers (p < 0,05). More- 
over, antlhypmlonslve therapy with ramlpdl affects these levels favorably. 
These observations raise the possibility that TGF~e may be another marker 
of the effectiveness of antlhypertenslve therapy. 
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~ 8uppmaslon 8ympathetlo 8ys~m o| Nervous 
AMIvlty and InareaNd inotmplo  ~ lkR~p. tor  
Responslv l ty Our ln9 Metopro io l  Tharapy in 
Elderly I~tlent= With CHF 
M,A, Supiano, M,R, Starling, ~rm~e~f  ot InWmal Medina, Card~ok)gy 
and Genafflcs SectJnns, University of It~ch~an: VA Medical Cen~s, Ann 
Art~¢, Mi, USA 
Aging and CHF are each associated with aympathshc nervous system ac- 
tivation (SNSa) and decreased ll-~tK:eplor rasponoivonoss. To betemtme if 
chronic ll.blocker therapy wou!d result in suppression of SNS a ~  and 
up.regulation of p.receplor esponsMty tn older CHF pahente, we measured 
plasma noreplnephnne (NEt levels, 3H.NE kinetic parameters, and inoh'Ol~C 
(dobutamtne.medlat ~d ir crease in velocity of ciroumferonlial tiber showte~ng, 
AVCF~) i'l-receptor respon,~e in ? subjects aged 62-79 yrs with LV SySIOIK; 
dysfunction (ejection fraction -~40%) at baseline and followed 6 months of 
metoprolol therapy, Compartmental analysis of plasma NE and ~H,NE levels 
obtained during ~H-NE infusion and dunng its decay was pedomx~ to deter- 
mine the extravascular NE release rate (NE~), an index ol systemic SNSa, 
and NE metabolic learance rate (MCR~), 
NE NE 2 MCRt VCF¢ AVCF¢ 
tPOtml) ',,g/mlntmg) (t~tmtnt~ t (cqm~sec) t~,w~-¢) 
Baseline 393±26 2.23±0.15 1.17±008 089±005 O 16 = O0..t 
Metopmloi 304 :t 33 184±OI7 1 02 ¢008 I04 ~:O 10 0.27¢0.05 
P value 0 01 0.004 O 06 0 17 005 
FoUowing meteprolol: 1) despite a fall in MCRt, plasma NE le~mls were 
significantly tower due to a decrease in NEe, suggesting suppression ot 
SNSa; and 2) VCFc tended to increase, and the &VCFc was sigelflcantly 
improved, suggesting enhanced myocardial contractility and an up-regulahon 
ot inotropic p-receptor esponsivity, 1"hera was also a signifcant improvemem 
in 6-sin walk distance (1268 4. 29 to 1370 ± 41 r; P = 0.02). Thus. chronic 
/~-blocker therapy in older patients with CHF appoam fo suppress SNSa, 
improve inotropric tl-raceptor esponsivity, and is associated with improved 
functional pedormanco. 
~ Plasma Atrial and Brain Natrluretl¢ Peptides In 
Elderly Patients With Heart  Failure due to 
Diastolic vs. Systolic Left Ventricular Dysfunct ion 
C.T. Marburger, P.H. Brubaker, T.M. Morgan, B. Brosnihan. DW. Kltzman. 
Bowman Gray School of Medicine of Wake Forest University. 
Winston.Salem, North Carolina, USA 
We recently reported that elderly patients with heart failure and a normal LV 
ejection traction (EF 69 ± 9%) and no coronary, valvular, or pulmonary dis- 
ease (presumed diastolic dysfunction, DD) have severe exemise intolerance 
equal to age-matched patients with severe systolic LV dysfunction (SD. EF 
29 • 10%). We now report plasma concentrations of atrial (ANP) and brain 
(BNP) natriuretic peptides by radioimmunoassay (CV 6'>/0 and 11% respec- 
tively) in these patients and in healthy age-matched volunteers (HV) during 
supine rest (REST), head up tilt table (TILT) and maximal bicycle exercise 
(EXERt. Data sh.Jwr~ as mean ± SEE. 'p < 0.05 and "'p < 0.01 vs HV) after 
log transformation and adjustment for age and gender. 
ANP BNP 
n rest tilt exer rest tilt 
ItV 21 14±11 14±11 38±14 10±30 16±37 39±48 
DD 42 30±7" 32±8" 46±10 55 + 20" 57 ± 26" 67±32 
$D 53 79.L7 °' 72 :L 7" 93±9- 155 :E 19 174±23" 198±29- 
JACC February 199~ 443A 
Rest and tilt ANP and BNP were olgniflcantly increesed tn DO vs  HV but 
not as much as in SD. ANP and BNP increased (p .~ 0,001) with exert. ~o 
in I!11 gfouDg, "rt~m was a modest relationship (r = 0,36, p -~ 0,05) bet~n 
BNP end exercise capacity (VO2mes) for OD I~ttk0n~ I:~ no mteti~Yt::,tp 
with ANP, 
C~-~=,.~ott: Eldedy patief~ with heat1 failure due to t:haltO~tc o~tun¢. 
tlon have eb~o~mal neuroendocnne function. Thin may play a role in 
I~n~d~ of ~c ise  ~nt~Io~,Jce in such ~t ler~.  
• r.,ontpmlWe Heart Fmllum In I~  Community: 
l~ ln~ In Im:ldm~:e Ind  8urvlvM Ovor 110-Year 
M Seem, CM, l"ntx~]loy, RJ, R ~ ,  J,M Evae~, S J, ~ ,  
KR, Bad~f, M,M Red~d- A4~fo C/in~ R'Jchest~, A4W, USA 
Th~ imp~'t o! a~ano~ m th~ ~ of can~ ~ on 1~e mo- 
demce (INC) o4 ( m ~  hMzl ~ (CHF) m I~e o~m1~y m t reks .  
L i~,  ~t m tmd~z w l~Hhe av~a~l~ at ACE ~ has i ~  
(SUR) in pls w(th CHF in tho ¢¢~mLm~y We ¢on~samd the INC at 
CHF and SUR in p!~ w~l  CHF in Re~hmm~, MNm lt~11 tO that ~ m 
~,  Um~ mo ~ Sp*demek~ ~ ,  we ~ aa p~s w.h a 
Itmt d~ ol CHF ( F ~  ~ )  m 1~1 (n = 107) ~ 1991 in = t41). 
M¢lest i~we~eldedy  amlttm mea~ ~e 1 75.0 .t. 14,7m 1~B1 and 77.4 ± 
11.7 ~ m 1~1 (ns). Tho 1ffi)1 i~  tram leu  ~ (NYHA Clas~ 27  
* 0.? vs. 3.2 ± t.4, p < 0.00t). INC ~ (pe~ 1,(~0 ~ )  adiusted 
Io~ age and sex to tho US popt~t~rt and SUR were; 
tNCM~ tNC Wome~ tNC~ t-~r SUR 5-1~' SU~ 
t04BI 37 z 1~,55 21 :029 2 8 :=: 0,~i T'Z% 34% 
1991 3L7" ¢ O.S ~6 ± O~ 30 ± 02~ 77~ ~0 
Neiffte~ INC no~ SUR acrlusted tour age, m a~l  NYHA Clas~ were ddtemm 
m 1981 vs. 1991./t~ room I~s who ¢le~'e~0~ CHF me e~Md~, U~ stabte INC 
el CHF m tho commmUty ~ mmgt m increasing prevalence ol CHF as me 
ixN)uMbon ages. De~pte the pm~m be~eM of ACE mhd~k~rs Ic, r CHF, SUR 
ol lhese ek:Mdy CHF pls m Ule communety ~s not bett~ m I1'~ "ACE mly, l~m 
efa~ 
tmpact of Cdtk~ PaUmay on me mmagemem at 
Acute M ~ I  ;,~;~,~;~n i me Eldedy 
RH. I~ohta. S_ Des. E. Nolan. G Keady. 0. Karmate. P Rus~tan. 
K. Sara~ J. Nckms, K_A. Eagle. Dn~s;On of CareeoZo~. Un~emty at 
MK~Ja~ Ann Ad~;M/, USA 
Bac~gmcmd: Eldedy patsems (PTS) may mcewe sub-.ol~mal care for acute 
myoca~al ~ (AMI). These ~r~tude tess use of ~ ff'mrapy and 
mvas~e i:~rocedums. In oedm to ensure ap~,c3nale cam m air age groups. 
we eslabJished a cnbcal part,ray fo~ ~ealment of AMI, based on fl~e ha- 
bonaz gc.de-~as. ,.',e~t o~,~,.,,:ed ~ey besptaz and dmchaege U'mrapms known 
to tmpem,,e outcomas after m~al management ot AML We examine here ffm 
ulN~qct ot adllem.nce to tt,s tool m dmemnt age 91roups. 
Methods: AMI aocounted for 540 ~,s~hazgas between 3Rt5 to 2/97 (mean 
age--62 y~; mates 362; tamales 178;). T h e ~  were detined as c~c~ to 
improve PTS outcomes: beta-blockers (BB); ace mhibitors (ACEi); avo~a~e 
ol calcium b/ockers (CB); lipid Iowenng agents (LPA); outpabent mhabtrttatmn 
(OR); smoking cassat~on (SC) and diet counseling (DC). 
Resu/fs: 
AGE N BB% ASA% ACE% CCB% LPA% 
~65 306 .<Fa.3 97.3 91 92.4 68 
65-80 195 93.7 984 8 ~' 89 2 63 
~80 39 90.9 100 86 91 2 43 
p - 0 44 046 O 41 050 0 03 
AGE SC% DC% OR% CATH% PTCA% 
~6S 95.7 97.3 79.4 79.8 553 
65-80 88.1 94.1 63.1 80.0 55,4 
-.80 0 (n = 1) 97L2 64.5 73.7 444 
p 0001 0.21 0.001 082 0.67 
• RI¢ I l l  Olffofoncel In RolponIo to ~ OlockM 
Therlpy in Elderly Patkmts Sufferln9 Acute 
Myocardial Inhlrctlon 
D. Will.ires, KS K,m, E, ,~iwa~yi, S Jain, B. [~N~ln~, C L, Cuf1~/'tow~ff 
Um~rr~y Hos/~a/, ~ DC USA 
The 8t.,nm~l benoffi Of t~ta.tdockof (/t/]) therapy m AMI (t! wtttt ¢~¢ument(~, 
The ~ C~rd~,~mc~la~ P  ~ = ~ Cam Ftr~m~ Ag~'V 
profe~ w~ • goal of mp~d~ q~a~y of cam m Mee~em i~ w~ AMI, 
We evalual~ Ihe OELMARVA ~ data Ht to d~4mmm~ ¢,,;.-~-~ m 
8uevlv01 from tttl IhemlPy ~ n  Whit~ ~ ~ tAe¢~em ~ wflh AMI. MI 
wa~ eo~em.e¢l by 2/"3 ot I~  ~lmv~ng:, ~ ,  c~rr.t~; m,,.Wm~, m'~t EC, G. 
Pelmnts leu  l~an 65 W~l) ~,hJck)d from imllyt~, Th(leb were 1 ~9,0~ pta, 
t44~ Whrk~ (W). 90~ Otactm (O). M~m ~:  W =/5  :t 1,4, O ; "/5,3 
• 7,4, O h4~ morn m~k ta¢1om tar CAD: HTN in O ,. 7194 (79,09%) ~ W 
= 87132 (80,41%) p ,~ 0.0001; ~ B '= 1043 (18,06%) Vt W '~ 2131~ 
(14.11~t%) p < 00001; Rn¢l 0M B ~ ~ (42,1%) v~ W = 4240? (20.4%). p 
0 .~1.  Sligi~y ~ wt~lo pls were II'eate4 with ~l/147.2% vii 44,3% (p .~ 
0.0001) e~uem0 I~e ~x h0~l~¢~lmn, Sun,wai at each tm~e ~r~e~d was 
e,gt~cantty ~ w~ eu~! wm~/~p t~mmy (p .,: 0.0ool): 
e monms 12~ 24 momt~ 
Whnes 
/~# g2% 00% 
No , .  68% ~2% 58% 
Backs 
No-rp ~ 66% SIP= 
~ Smilax s,,.~'~wal be,,~¢i wes ,~,~,k~ from tP, e Im~mem ot 
• Outcomu an~ ~ k m  .~mocbCld Wlth Ua  
comm,~ Imm~m.llo,~ 
CL L_~core, R.V Trask, GJ. I ~  RJ._ Kacch, KJ. Flocha-Singh, 
H.W. Moses, FL  Mkeil, MF_ Shellon, FLW. Ligon. Prame CaMo~lscu/ar 
C~ams.  L~, ~ mx~s. USA 
To evahJate the effects of abcmmam on e;,~,~,y pastures, outcomes and cosls 
of ~ co.-¢.-,~,-./~:x-,s h'om 1/96-6/97 were as~m~md fm I1~ee 
groups: I=age >70wdPn abcmmab Rx; II = age _>70 wllbOut abcmimab Rx; 
III = acj~ <_69 ~t l l  ~¢~lab  Rx. 
Groc, p I II III 
Age yt' x ~SO ( ramge ) 76¢5(70-91) 76 ¢ 5 (70--g3) 57 ± 9 (24-69).1 
N= 309 622 593 
Deem% 16 23 0,3" 
P.e-PTCA % 03 03 0,3 
~ %  10 15 07 
C~T,~,,~te % 32 47 19" 
Bfc, edmg % 26 I 6 02 .1 
LOS day 4 0 44 32 "1 
Hasp Cost $11 666 S9954 t S10,668 
Cu~voos, fe = 0¢,a111 .~ I~ ,, Fle-PTCA + CABG; "p - 001 v.~. geoulp I1; tp • 001 vl~ 0mop 
I 
Logfsllc m ~  ide~tfmd muflTvessei CAD (~ rabo [OR] 3.5. 95% 
CI: 14-102), female gender (OR 3.3. CI 1.3-8.1). and SVG mlet~ 
(OR 3.7, CI 1.3-10.7) as I:~edtctors of adverse events in pa1~lts mceMng 
ab~xm~b dunng hospC~zatmn (p < 0O2) Beedmg was greatm m be~ 
groups of eldedy pat~s  comCmrsd to yo~-C,e,- pabents, but was rmt related 
slgnif~:antty to abaximab Rx. Thus. use of abdxlmab in elderly pu~.~ 
is assoc~ted w~th hospdal costs samilar to ymmger patm~s and excellent 
outcomes. 
Conclusion: 1. Use of a critical pathway was assooated with high adher- 
ence to most quality indicators across all ages. 
2. Lower use of LPA and OR in the eldedy may reflect physician uncertainty 
as to their benefit in this cohort and deserves fudher study. 
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